Amivantamab-Vmjw

Introduction Overview

Generic Name

amivantamab-vmjw

Brand Name

Rybrevant

Dosage Form

Injection for intravenous infusion (350 mg/7 mL)

Drug Class

Miscellaneous bispecific antibodies

Pharmacokinetics

Absorption:
Rybrevant (amivantamab-vmjw) is administered as an intravenous infusion, which allows direct entry into systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism. This route results in complete bioavailability of the agent. As a large bispecific monoclonal antibody, Rybrevant is not absorbed via oral administration and requires IV infusion to achieve therapeutic plasma concentrations.

Distribution:
Following IV administration, Rybrevant distributes primarily within the vascular and interstitial compartments. Monoclonal antibodies such as amivantamab have limited volume of distribution approximating plasma volume, typically ranging around 3-6 L. The bispecific antibody demonstrates high affinity binding to extracellular domains of EGFR and MET receptors on tumor cells, which may influence its distribution by targeting tumor microenvironments. Limited penetration across physiological barriers such as the blood-brain barrier is expected due to molecular size.

Metabolism:
Like other therapeutic antibodies, Rybrevant is metabolized primarily via proteolytic catabolism into smaller peptides and amino acids by reticuloendothelial system cells. This degradation occurs through lysosomal pathways mediated by macrophages and target-mediated endocytosis following binding to EGFR and MET receptors. Unlike small molecules, Rybrevant is not metabolized by cytochrome P450 enzymes, reducing potential for hepatic enzyme-based drug-drug interactions.

Elimination:
The elimination of Rybrevant involves a combination of target-mediated and nonspecific catabolic pathways. The half-life of amivantamab allows for dosing every 1 to 3 weeks, reflecting slow clearance through proteolytic degradation. Clearance may be influenced by target expression levels and tumor burden. There is no significant renal or hepatic excretion of intact molecule. The pharmacokinetics are also affected by body weight, with dosing differentiated by <80 kg and ≥80 kg to optimize exposure.

Overall, the pharmacokinetic profile of Rybrevant as a bispecific antibody supports infrequent intravenous dosing, targeted delivery to tumor cells expressing EGFR and MET, and predictable metabolism and clearance without involvement of hepatic cytochrome systems.

Dosage Forms

Available Dosage Forms:
- Rybrevant is available as a sterile, preservative-free solution for intravenous infusion.
- The single-dose vial contains 350 mg of amivantamab-vmjw in 7 mL (50 mg/mL) concentration.

Dosages for Adults and Adolescents:
- For adult patients under 80 kg body weight receiving Rybrevant as monotherapy or in combination with lazertinib:
- Weeks 1 through 5: 1050 mg IV infusion weekly
- Week 7 onward: 1050 mg IV infusion every 2 weeks
- For adult patients 80 kg or greater receiving Rybrevant as monotherapy or with lazertinib:
- Weeks 1 through 5: 1400 mg IV infusion weekly
- Week 7 onward: 1400 mg IV infusion every 2 weeks
- For patients receiving Rybrevant in combination with chemotherapy agents carboplatin and pemetrexed:
- Patients under 80 kg:
- Weeks 1 through 4: 1400 mg IV infusion weekly
- Week 7 onward: 1750 mg IV infusion every 3 weeks
- Patients 80 kg or greater:
- Weeks 1 through 4: 1750 mg IV infusion weekly
- Week 7 onward: 2100 mg IV infusion every 3 weeks

Specific Patient Populations:
- The dosing regimen may be adjusted based on patient weight.
- Pre-medications such as antihistamines, antipyretics, and glucocorticoids are often administered before infusion to minimize infusion-related reactions.
- Patients with advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions, exon 21 L858R mutations, or exon 20 insertions are candidates for tailored Rybrevant dosing.
- Safety and efficacy have not been established in pediatric populations.
- Dose modifications or interruptions may be required for serious adverse reactions or infusion-related toxicities.
- Special monitoring is recommended for patients with pulmonary, dermatologic, or ocular comorbidities.

Clinical guidelines emphasize careful patient weight-based dosing and therapeutic monitoring to optimize efficacy and safety profiles.

Mechanism Of Action

Rybrevant (amivantamab-vmjw) is a fully humanized bispecific monoclonal antibody that simultaneously targets two critical receptor tyrosine kinases involved in oncogenesis: epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). By binding specifically to the extracellular domains of EGFR and MET on tumor cell surfaces, Rybrevant blocks ligand binding and receptor activation, thereby inhibiting downstream signaling pathways that promote tumor cell proliferation, survival, migration, and metastasis.

The bispecific design enables Rybrevant to engage EGFR and MET simultaneously, disrupting their crosstalk and overcoming resistance mechanisms often mediated by MET amplification or mutation in non-small cell lung cancer (NSCLC). Upon receptor binding, Rybrevant not only blocks receptor activation but also induces internalization and degradation of EGFR and MET, further reducing oncogenic signaling.

Beyond direct receptor inhibition, Rybrevant mediates immune effector functions by engaging Fc gamma receptors on immune cells such as natural killer (NK) cells and macrophages. This engagement triggers antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis, facilitating immune-mediated destruction of tumor cells expressing EGFR and MET. This dual mechanism—targeted receptor blockade combined with immune engagement—enhances antitumor efficacy.

Clinical studies have demonstrated that Rybrevant is particularly effective against NSCLC tumors harboring EGFR exon 19 deletions, L858R substitutions, and exon 20 insertion mutations. When combined with the tyrosine kinase inhibitor lazertinib, Rybrevant shows synergistic anti-tumor activity, likely due to complementary inhibition of EGFR signaling pathways at the extracellular and intracellular kinase domains. This innovative bispecific antibody approach represents a significant advance over traditional EGFR inhibitors by addressing multiple resistance pathways and engaging the immune system to achieve improved clinical outcomes in patients with advanced NSCLC.

Pharmacological Actions

Bispecific inhibition of EGFR and MET receptor tyrosine kinases to block tumor growth signaling.
Induction of receptor internalization and degradation leading to decreased oncogenic signaling.
Mediation of antibody-dependent cellular cytotoxicity (ADCC) via Fc receptor engagement to recruit natural killer cells and macrophages.
Induction of trogocytosis promoting immune-mediated tumor cell destruction.
Synergistic anti-tumor effects when combined with tyrosine kinase inhibitors like lazertinib.
Targeted therapeutic approach for NSCLC patients with specific EGFR mutations including exon 19 deletions, L858R, and exon 20 insertions.
Overcoming resistance mechanisms associated with MET amplification or mutation in EGFR-mutated NSCLC.
Prolonged duration of tumor response due to combined direct receptor blockade and immune effector functions.
Intravenous administration ensuring direct systemic delivery to tumor sites.
Non-chemotherapy mechanism, allowing use in combination with chemotherapy agents without overlapping toxicities.
Potential to enhance efficacy of carboplatin and pemetrexed chemotherapy via combinatorial effects.
Reduction of cellular proliferation, survival, migration, and tumor metastasis signaling pathways.
Minimal cytochrome P450 enzyme involvement reducing risk of metabolic drug interactions.
Demonstrated clinical activity in diverse mutation subsets of advanced NSCLC.
Pre-medication reduces infusion-related hypersensitivity reactions enhancing patient tolerability.

Therapeutic Or Clinical Uses

Treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations in combination with lazertinib as first-line therapy.
Management of EGFR exon 19 deletion or exon 21 L858R mutated NSCLC patients whose disease progressed following EGFR tyrosine kinase inhibitor treatment, in combination with carboplatin and pemetrexed chemotherapy.
First-line treatment for NSCLC with EGFR exon 20 insertion mutations in combination with carboplatin and pemetrexed.
Monotherapy in adult patients with EGFR exon 20 insertion-mutated NSCLC whose disease progressed on or after platinum-based chemotherapy.
Targeted therapy option specifically approved for EGFR-mutated NSCLC where surgical resection is not feasible.
Therapeutic alternative to conventional chemotherapy with a distinct mechanism and side effect profile.
Useful in overcoming resistance to prior EGFR-targeted tyrosine kinase inhibitors.
Part of combination regimens that improve progression-free survival and overall response rates in clinical trials such as MARIPOSA and PAPILLON.
Treatment for advanced NSCLC patients with metastatic disease requiring systemic therapy.
Option for patients intolerant or refractory to platinum-based chemotherapy.
Potential to be used in combination with immunotherapy or other targeted agents under clinical investigation.
Treatment modality that integrates targeted receptor blockade with immune-mediated tumor cell kill.
Indicated for patients with poor prognosis and limited therapeutic options due to EGFR mutations.
Can lead to durable tumor response with manageable safety profile.
Approved by the FDA as a breakthrough therapy for specific EGFR-mutated NSCLC indications.

Side Or Adverse Effects

Rash, including severe skin reactions such as blistering, peeling, and eczema-like presentations.
Paronychia and infection around the nails.
Muscle and joint pain (myalgia and arthralgia).
Mucositis including sores and ulcers in the mouth.
Peripheral edema and generalized swelling of hands, feet, face, or limbs.
Paresthesia or unusual sensations in the skin such as tingling or crawling feelings.
Fatigue and malaise, frequently reported and sometimes severe.
Gastrointestinal symptoms including diarrhea, constipation, nausea, and vomiting.
Dry and itchy skin with pruritus.
Increased susceptibility to infections including COVID-19.
Bleeding complications evidenced by changes in blood coagulation parameters.
Laboratory abnormalities including altered blood cell counts and liver enzyme elevations.
Respiratory symptoms such as shortness of breath and cough.
Serious infusion-related reactions including anaphylaxis, hypotension, flushing, and chest discomfort.
Eye disorders such as inflammation, itching, pain, redness, blurred vision, and excessive tearing.

Precautions

Administer pre-medications including antihistamines, antipyretics, and corticosteroids to reduce infusion-related reaction risk.
Monitor patients closely during and after infusion for signs of hypersensitivity reactions.
Limit sun exposure during treatment and for at least two months post-treatment to reduce photosensitivity and skin reactions; use protective clothing and broad-spectrum sunscreen.
Obtain baseline and periodic lung function assessment due to risk of potentially fatal pulmonary toxicity.
Monitor for signs and symptoms of blood clots, especially deep vein thrombosis and pulmonary embolism, particularly when used with lazertinib.
Discontinue or interrupt therapy in the event of severe dermatologic, pulmonary, or ocular toxicities.
Avoid use in pregnant women due to potential fetal harm; require negative pregnancy test before initiation and effective contraception during and for 3 months after therapy.
Advise against breastfeeding during therapy and for 3 months afterwards due to unknown drug excretion in milk.
Assess baseline ophthalmologic status and refer to ophthalmologist promptly if ocular symptoms develop during treatment.
Adjust dose or delay treatment for serious adverse reactions according to clinical guidelines.
Monitor blood counts and biochemical parameters regularly to detect laboratory abnormalities.
Use caution in patients with pre-existing dermatologic, pulmonary, cardiovascular, or immune disorders.
Provide patient education regarding symptoms necessitating urgent medical attention such as shortness of breath, severe rash, or swelling.
Ensure prompt intervention at first signs of infusion reactions to avoid progression to anaphylaxis.
Coordinate multidisciplinary care involving dermatology, pulmonology, and ophthalmology specialties as needed.

Warnings

Infusion-Related Reactions: Common and potentially severe, including life-threatening anaphylaxis requiring immediate discontinuation and supportive care.
Pulmonary Toxicity: Risk of lung problems including interstitial lung disease and pneumonitis that may be fatal; monitor for new or worsening respiratory symptoms.
Thromboembolic Events: Increased incidence of blood clots such as deep vein thrombosis and pulmonary embolism, especially when combined with lazertinib; prophylactic anticoagulation for first 4 months recommended.
Severe Skin Reactions: Potential for serious dermatologic adverse events including Stevens-Johnson syndrome or toxic epidermal necrolysis; prompt identification and treatment is essential.
Ocular Toxicity: Risk of keratitis, conjunctivitis, or eyelid inflammation that may lead to vision changes; avoid contact lenses until symptoms are evaluated.
Embryo-Fetal Toxicity: Can cause fetal harm; contraindicated in pregnancy and requires contraception during and after treatment.
Laboratory Abnormalities: Possible hematologic and biochemical disturbances requiring routine monitoring to prevent serious complications.
Delayed or missed doses may compromise therapeutic efficacy; maintain scheduled infusions when possible.
Potential for serious infections due to immunomodulatory effects of combined therapy.
No established safety in pediatric populations; contraindicated or use with caution in these demographics.
Treatment interruptions or discontinuation may be required for serious adverse events or intolerable side effects.
Close monitoring during early infusions is critical to detect hypersensitivity reactions timely.
No data on long-term safety; vigilance for late-onset toxicities recommended.
Concurrent use with other EGFR/MET inhibitors may increase toxicity risk and is generally not advised.
Patients should be informed about signs of severe adverse effects and instructed to seek immediate medical care if they occur.

Contraindication

Known hypersensitivity to amivantamab-vmjw or any component of the formulation.
History of severe hypersensitivity or anaphylactic reaction to Rybrevant or similar monoclonal antibodies.
Pregnancy due to potential teratogenic effects and fetal harm.
Breastfeeding due to unknown risk of drug excretion and infant exposure.
Use in pediatric patients under evaluation, currently not recommended or established due to lack of safety data.
Concurrent administration with other EGFR or MET targeted therapies outside of approved combination regimens without established safety.
Uncontrolled severe lung or respiratory diseases that may exacerbate pulmonary toxicity risk.
Known active bleeding disorders or coagulopathy without appropriate management, due to bleeding risk.
Severe dermatologic conditions may contraindicate use until stabilized.
Known infections or immune compromised states that contraindicate immunomodulatory antibody therapy without adequate prophylaxis.
Patients unable to comply with monitoring or treatment scheduling due to risk of severe adverse event under-treatment.
Known intolerance to pre-medications required to reduce infusion reactions.
Severe renal or hepatic impairment without dose adjustment or careful monitoring may be contraindicated.
Concurrent participation in investigational drug studies unless approved by treating physician.
Any condition judged by the healthcare provider to pose unacceptable risk from Rybrevant therapy.

Drug Interactions

No formal drug interaction studies conducted; potential interactions unknown but expected to be minimal due to antibody metabolism pathways.
Possible interaction with immunosuppressive agents could increase risk of infections or reduce effectiveness.
Concurrent use with other EGFR or MET inhibitors may increase toxicity and side effect burden.
Combination with chemotherapy agents carboplatin and pemetrexed is approved and used clinically with enhanced efficacy but requires monitoring for additive toxicities.
Potential pharmacodynamic interactions with anticoagulants due to increased thrombosis risk when used with lazertinib.
Co-administration with glucocorticoids or antihistamines as pre-medications reduces infusion reactions but may modulate immune responses.
No significant cytochrome P450 enzyme involvement limits interaction with metabolic enzyme inducers or inhibitors.
Limited evidence regarding interactions with herbal supplements or vitamins; caution advised and healthcare provider informed of all concomitant products.
Potential additive myelosuppression with other bone marrow suppressive drugs necessitating complete blood count monitoring.
No known interactions with oral contraceptives but contraceptive efficacy may be compromised if vomiting or diarrhea occurs.
Medications affecting fluid balance should be used with caution due to potential for Rybrevant-associated edema.
Live vaccines should be avoided during treatment due to immunomodulatory effects.
No established interactions with supportive care medicines but careful review is recommended.
Interaction potential with other biologics not established; concurrent use requires clinical discretion.
Monitoring required when combining with drugs that prolong QT interval due to unknown risks.

Preparations Of The Drug

Rybrevant is supplied as a sterile, preservative-free solution in single-dose vials containing 350 mg of amivantamab-vmjw per 7 mL (50 mg/mL).
The solution contains inactive ingredients such as EDTA disodium salt dihydrate, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80, sucrose, and water for injection.
Vials are intended for intravenous infusion only and must be diluted appropriately prior to administration according to manufacturer instructions.
The drug should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light until use.
Discard unused portions as the product is preservative-free to avoid contamination.
Preparation involves aseptic handling to prevent microbial contamination during dilution and infusion bag preparation.
Infusion solutions commonly use 0.9% sodium chloride injection for dilution to required volume.
Dosing schedules vary depending on patient weight and therapeutic regimen including monotherapy or combination therapy.
Premedication with antihistamines, antipyretics, and glucocorticoids is recommended to mitigate infusion reactions.
Instructions advise slow initial infusion rates to minimize infusion-related adverse events, with increased rates if tolerated.
Single-use vials are for one patient only; any residual drug must be discarded following administration guidelines.
Detailed prescribing information and package inserts provide preparation protocols, storage, stability, and administration instructions to healthcare personnel.
Manufactered and distributed by Janssen Biotech, a subsidiary of Johnson & Johnson.
No generic or biosimilar equivalents currently available; Rybrevant remains the innovator biologic product.
Preparation should be performed by trained healthcare professionals within controlled clinical or hospital settings.